A week after swaying an FDA panel with its colorectal cancer screen, Exact Sciences ($EXAS) raised $119.7 million through a stock offering, flipping 10 million shares at $12.75 each. With the proceeds, the company plans to pay Cologuard's way through FDA approval, eventually launching the stool-based cancer diagnostic. Release